REG - BioPharma Credit PLC - Result of AGM

Biopharma CreditAnnouncement

12/06/2024 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240612:nRSL1955Sa&default-theme=true

RNS Number : 1955S  BioPharma Credit PLC  12 June 2024

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

 

RESULT OF 2024 ANNUAL GENERAL MEETING

 

The Company is pleased to announce that, at the Annual General Meeting held
today, all resolutions put to the meeting were passed by way of a poll.

 

 

 Resolutions                                                                  Votes        %        Votes Against  %       Total Votes  % of Total Voting Rights Voted  Votes Withheld(1)

                                                                              For
 1: To receive and accept the annual report and financial statements          558,898,973  99.99%   52,892         0.01%   558,951,865  45.85%                          28,112
 2: To approve the Directors' Remuneration Report                             558,576,994  99.97%   177,879        0.03%   558,754,873  45.83%                          225,104
 3: To receive and approve the Directors' Remuneration Policy                 558,551,021  99.96%   227,616        0.04%   558,778,637  45.84%                          201,340
 4: To re-elect Harry Hyman as a Director                                     494,888,417  99.99%   66,478         0.01%   494,954,895  40.60%                          64,025,082
 5: To re-elect Colin Bond as a Director                                      558,759,159  99.99%   76,104         0.01%   558,835,263  45.84%                          144,714
 6: To re-elect Duncan Budge as a Director                                    494,888,417  88.56%   63,946,846     11.44%  558,835,263  45.84%                          144,714
 7: To re-elect Stephanie Léouzon as a Director                               558,780,785  99.99%   54,478         0.01%   558,835,263  45.84%                          144,714
 8: To re-elect Sapna Shah as a Director                                      558,780,762  99.99%   54,478         0.01%   558,835,240  45.84%                          144,737
 9: To re-elect Rolf Soderstrom as a Director                                 558,744,159  99.99%   76,104         0.01%   558,820,263  45.84%                          159,714
 10: To re-appoint Ernst & Young LLP as Auditor to the Company                558,682,815  99.96%   204,636        0.04%   558,887,451  45.84%                          92,526
 11: To authorise the Directors to determine the remuneration of the Auditor  558,769,161  99.99%   69,478         0.01%   558,838,639  45.84%                          141,338
 12: To approve the Company's dividend payment policy                         558,978,176  100.00%  1,801          0.00%   558,979,977  45.85%                          0
 13: To authorise the allotment of shares by the Company                      556,785,857  99.62%   2,150,350      0.38%   558,936,207  45.85%                          43,770
 14: To authorise the disapplication of pre-emption rights                    556,858,554  99.63%   2,077,653      0.37%   558,936,207  45.85%                          43,770
 15: To authorise the Company to make market purchases                        558,895,163  99.98%   84,814         0.02%   558,979,977  45.85%                          0

 of ordinary shares
 16: To authorise the Company to hold general meetings                        558,867,851  99.98%   99,598         0.02%   558,967,449  45.85%                          12,528

 on 14 clear days' notice

 

1.     A 'vote withheld' is not a vote under English law and is not
counted in the calculation of votes 'for' or 'against' a resolution.

 

Copies of resolutions 13 to 16 have been submitted to the National Storage
Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

12 June 2024

 

 

Enquiries

 

BioPharma Credit plc

 

via Link Company Matters Limited

 

Company Secretary

 

T. +44 (0) 333 300 1950

 

Buchanan

 

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

 

+44 (0) 20 7466 5000

 

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

 

 

Notes to Editors:

 

BioPharma Credit PLC is London's only listed specialist investor in debt from
the life sciences industry and joined the LSE on 27 March 2017. The Company
seeks to provide long-term shareholder returns, principally in the form of
sustainable income distributions from exposure to the life sciences industry.
The Company seeks to achieve this objective primarily through investments in
debt assets secured by royalties or other cash flows derived from the sales of
approved life sciences products.

 

 

 

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSFIFLEELSESM